Evodiamine targets ZO-1 to ameliorate cholestatic liver disease: Intestinal homeostasis as the core mediator of gut-liver axis repair and bile acid metabolism remodeling
Phytomedicine · 2026-07 · 157 · 158288
DOI: 10.1016/j.phymed.2026.158288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-07. Verfasst von Shuxin Yan und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. Hauptthemen laut MEDLINE: Zonula Occludens-1 Protein, Bile Acids and Salts, Quinazolines, Cholestasis. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
BACKGROUND Cholestatic liver disease (CLD) is a complex and multifactorial chronic disorder that requires a systematic and integrative management. Evodiamine (EVO), a natural alkaloid derived from Evodiae Fructus, has demonstrated significant therapeutic potential in ameliorating digestive diseases. However, the beneficial effects of EVO on CLD and the underlying mechanisms remain poorly understood. OBJECTIVE This study aims to elucidate the mechanisms through which EVO modulates the progression of CLD, with a particular focus on the regulation of gut-liver axis homeostasis. METHODS The therapeutic efficacy of EVO in bile duct ligation (BDL)- and α-naphthyl isothiocyanate (ANIT)-induced CLD rat models was systematically evaluated. An integrative approach combining network pharmacology with multi-omics analyses (transcriptomic, metagenomic sequencing, targeted bile acid metabolomics) was employed to identify significantly altered molecular networks. Fecal microbiota transplantation (FMT) was conducted to validate the functional role of gut microbiota in the hepato-intestinal protective effects. Direct molecular targets as well as the functional validation were confirmed through molecular docking, pull-down assays, surface plasmon resonance and cellular thermal shift assay. RESULTS EVO achieved significant synchronous hepato-intestine protection in both CLD rats: it markedly ameliorated hepatic injury and hepatic fibrosis, downregulated pro-inflammatory cytokine levels, while preserving intestinal barrier integrity and alleviating intestinal inflammation. Mechanistically, EVO exerted these protective effects by directly targeting the tight junction protein ZO-1 and enhancing its expression and stability. Furthermore, EVO restored intestinal microbial homeostasis, corrected dysregulated BA metabolism-specifically normalizing deoxycholic acid (DCA) levels. FMT experiments demonstrated that the synchronous hepato-intestinal beneficial effects of EVO were partially mediated by gut microbiota. CONCLUSION EVO exerts a protective effect against CLD by directly targeting ZO-1 to strengthen intestinal barrier function, thereby restoring gut microbial balance and rebalancing BAs metabolism (especially DCA levels) in the gut-liver axis. This study uncovers a novel ZO-1-dependent mechanism of EVO in CLD, highlighting EVO as a promising candidate for the treatment of CLD and providing new insights into gut-liver axis-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
- Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China; Traditional Chinese Medicine Processing Technology Inheritance Base of National Adm…
- College of Medicine, Xinyang Normal University, Henan Province, 464000, China.
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
- School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: tangyang@bucm.edu.cn.
Förderung
- Natural Science Foundation of Beijing Municipality
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Yan, S., Zhang, Y., Fan, Q., Jia, W., Dai, Y., Li, X., Lu, S., Sheng, Y., Sun, S., Lin, R., Tang, Y., & Zhao, C. (2026). Evodiamine targets ZO-1 to ameliorate cholestatic liver disease: Intestinal homeostasis as the core mediator of gut-liver axis repair and bile acid metabolism remodeling. Phytomedicine, 157, 158288. https://doi.org/10.1016/j.phymed.2026.158288
Vancouver
Yan S, Zhang Y, Fan Q, Jia W, Dai Y, Li X, et al. Evodiamine targets ZO-1 to ameliorate cholestatic liver disease: Intestinal homeostasis as the core mediator of gut-liver axis repair and bile acid metabolism remodeling. Phytomedicine. 2026;157:158288. doi:10.1016/j.phymed.2026.158288
BibTeX
@article{Yan2026,
author = {Yan, Shuxin and Zhang, Yao and Fan, Qiqi and Jia, Wenwen and Dai, Yihang and Li, Xinlin and Lu, Shan and Sheng, Yuhan and Sun, Shuang and Lin, Ruichao and Tang, Yang and Zhao, Chongjun},
title = {Evodiamine targets ZO-1 to ameliorate cholestatic liver disease: Intestinal homeostasis as the core mediator of gut-liver axis repair and bile acid metabolism remodeling},
journal = {Phytomedicine},
year = {2026},
volume = {157},
pages = {158288},
doi = {10.1016/j.phymed.2026.158288}
}
EUVIMED